Tuberculosis Vaccines: Beyond BCG
Author Information
Author(s): Helen McShane
Primary Institution: The Jenner Institute, University of Oxford
Hypothesis
Can new tuberculosis vaccines provide better protection than the existing BCG vaccine?
Conclusion
There has been significant progress in developing new tuberculosis vaccines, but efficacy testing remains essential to determine their effectiveness in humans.
Supporting Evidence
- BCG provides consistent protection against TB meningitis and disseminated TB in children.
- New vaccines are focused on inducing a strong cellular immune response.
- Clinical trials are necessary to evaluate the efficacy of new TB vaccines.
Takeaway
Scientists are trying to make better vaccines for tuberculosis than the old one called BCG, which doesn't work well for everyone. They are testing new ideas to see if they can help people stay healthy.
Methodology
The article reviews various tuberculosis vaccine candidates and their development stages, focusing on their safety and immunogenicity in clinical trials.
Limitations
The lack of reliable immune correlates and predictive animal models makes it challenging to evaluate vaccine efficacy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website